Why ABPM should be mandatory in all trials of blood pressure-lowering drugs

Drug Information Journal

Volumn 45, Issue 3, 2011, Pages 233-239

  O'Brien, Eoin ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; PLACEBO;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE VARIABILITY; BORDERLINE HYPERTENSION; CLINICAL TRIAL (TOPIC); DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE COST; HUMAN; HYPOTENSION; MANDATORY PROGRAM; MORBIDITY; MORTALITY; NOCTURNAL HYPERTENSION; PLACEBO EFFECT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTOLIC BLOOD PRESSURE; WHITE COAT HYPERTENSION;

EID: 80051808086     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286151104500303     Document Type: Article

References (35)

1. O'Brien E. Ambulatory blood pressure measurement: the case for implementation in primary care. Hypertension. 2008;51;1435-1441.
2. Floras JS. Ambulatory blood pressure: facilitating individualized assessment of cardiovascular risk. J Hypertens. 2007;25:1565-1568.
3. O'Brien E. The value of 24-hour blood pressure monitoring to assess the efficacy of antihypertensive drug treatment. Hot Topics Hypertens. 2011;4:6-23.
4. Parati G, Ulian L, Sampieri L, et al., on behalf of the Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation (SAMPLE) Study Group. Attenuation of the "whitecoat effect" by antihypertensive treatment and regression of target organ damage. Hypertension. 2000; 35:614-620.
5. Owens P, Atkins N, O'Brien E. Diagnosis of white coat hypertension by ambulatory blood pressure monitoring. Hypertension. 1999;34:267-272.
6. Pickering TG, James GD, Boddie C, Harshfield GA, Blank S, Laragh JH. How common is white coat hypertension? JAMA. 1988;59:225-228.
7. Verdecchia P, Staessen JA, White WB, Imai Y, O'Brien ET. Properly defining white coat hypertension. Eur Heart J. 2001;23:106-109.
8. Mancia G, Parati G. Office compared with ambulatory blood pressure in assessing response to antihypertensive treatment: a meta-analysis. J Hypertens. 2004;22:435-445.
9. Conway J. Ambulatory blood pressure and clinical trials. J Hypertens. 1991;9(suppl):S57-S60.
10. O'Brien E. The circadian nuances of hypertension: a reappraisal of 24-h ambulatory blood pressure measurement in clinical practice. Ir J Med Sci. 2007;176:55-63.
11. O'Brien E. Ambulatory blood pressure monitoring: 24-hour blood pressure control as a therapeutic goal for improving cardiovascular prognosis. Medicographia. 2010;32:241-249.
12. Bilo G, Parati G. Temporal blood pressure patterns and cardiovascular events: "good night" or "good morning"? J Hypertens. 2006;24:1703-1705.
13. Dolan E, Stanton A, Thijs L, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality. The Dublin Outcome Study. Hypertension. 2005;46:156-161.
14. Rothwell PM, Howard SC, Dolan E, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010;375: 895-905.
15. Rothwell PM, Howard SC, Dolan E, et al., on behalf of the ASCOT-BPLA and MRC Trial Investigators. Effects of β blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol. 2010; 9:469-480.
16. Dolan E, O'Brien E. Blood pressure variability: clarity for clinical practice. Hypertension. 2010; 56:179-181.
17. Dolan E, Thijs L, Li Y, et al. Ambulatory arterial stiffness index as a predictor of cardiovascular mortality in the Dublin outcome study. Hypertension. 2006;47:365-370.
18. Parati G, Schumacher H, Bilo G, Mancia G. Evaluating 24-h antihypertensive efficacy by the smoothness index: a meta-analysis of an ambulatory blood pressure monitoring database. J Hypertens. 2010;28:2177-2183.
19. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-convertingenzyme inhibitor, ramipril, on cardiovascular events in high risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.
20. Owens P, O'Brien ET. Hypotension in patients with coronary disease-can profound hypotensive events cause myocardial ischaemic events? Heart. 1999;82:477-481.
21. Min SS, Turner JR, Nada A, et al. Evaluation of ventricular arrhythmias in early clinical pharmacology trials and potential consequences for later development. Am Heart J. 2010;159:716-729.
22. O'Brien E, Cox J, O'Malley K. Ambulatory blood pressure measurement in the evaluation of antihypertensive drug effect. In: O'Brien E, O'Malley K, eds. Blood Pressure Measurement. In: Birkenhager WH, Reid JL, eds. Handbook of Hypertension. Amsterdam: Elsevier; 1991:245-260.
23. Bevan AI, Honour AT, Stott FH. Direct arterial pressure recording in unrestricted man. Clin Sci. 1969;36:329-344.
24. Kain HK, Hinman AT, Sokolow M. Arterial blood pressure measurements with a portable recorder in hypertensive patients. I. Variability and correlation with casual pressures. Circulation. 1964; 30:882-892.
25. O'Brien E, Fitzgerald D. The history of indirect blood pressure measurement. In: O'Brien E, O'Malley K, eds. Blood Pressure Measurement. In: Birkenhager WH, Reid JL, eds. Handbook of Hypertension. Amsterdam: Elsevier; 1991:1-54.
26. O'Brien E, Atkins N. Can improved software facilitate the wider use of ambulatory blood pressure measurement in clinical practice? Blood Press Monit. 2004;9:237-241.
27. Fan HQ, Li Y, Thijs L, Hansen TW, et al., on behalf of the International Database on Ambulatory blood pressure in relation to Cardiovascular Outcomes (IDACO) Investigators. Prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from 10 populations. J Hypertens. 2010;28:2036-2045.
28. US Food and Drug Administration, International Conference on Harmonization. Draft guidance: E12A principles for clinical evaluation of new antihypertensive drugs. 2000. http://www.fda.gov/RegulatoryInformation/Guidances/ucm129461.htm and http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm129462.p df (accessed October 4, 2010).
29. US Food and Drug Administration, International Conference on Harmonization. Guidance on statistical principles for clinical trials; availability. Fed Register. 1998;63:49583-49598. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM129505.p df (accessed October 4, 2010).
30. International Conference on Harmonization. Topic E12: principles for clinical evaluation of new antihypertensive drugs. CPMP/ICH/541/2000.
31. European Medical Agency, Committee for Medicinal Products for Human Use. Guideline on clinical investigation of medicinal products in the treatment of hypertension. CPMP/EWP/238/ 95 Rev. 3 (Draft). 2009. http://www.ema.europa.eu/pdfs/human/ewp/023895endraft.pdf (accessed October 4, 2010).
32. O'Brien E, Asmar R, Beilin L, et al., on behalf of the European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens. 2003;21:821-848.
33. McGowan N, Atkins N, O'Brien E, Padfield P. Computerised reporting improves the clinical use of ambulatory blood pressure measurement. Blood Press Monit. 2010;15:115-123.
34. Li Y, Wang J-G, Dolan E, et al. Ambulatory arterial stiffness index derived from 24-hour ambulatory blood pressure monitoring. Hypertension. 2006; 47:359-364.
35. O'Brien E, O'Malley K, Cox J, Stanton A. Ambulatory blood pressure monitoring in the evaluation of drug efficacy. Am Heart J. 1991;121:999-1006.